Shlomi Nachman Joins AtriCure’s Board of Directors

AtriCure Inc. has appointed Shlomi Nachman to its Board of Directors. Nachman’s long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson’s Medical Devices business.

“I am thrilled that Shlomi has joined the Board of Directors,” AtriCure President/CEO Michael Carrel said. “He is one of the most well-respected leaders in the medical device space, having led Johnson & Johnson’s medical device business through a period of unprecedented growth. His experience in the Afib market will be invaluable as we continue our mission of healing the lives of those affected by this global epidemic.”
 
Nachman has more than 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beckman Foundation, an organization focused that supports research in chemistry and life sciences. Previously, he held senior operating roles at Johnson & Johnson, where he was the Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson’s Medical Devices business. He was a member of the Medical Devices Group Operating Committee and led a diverse portfolio of six medical device businesses including Electrophysiology, Neurovascular Intervention, Ear, Nose & Throat, Breast Aesthetics, Optometry, and Ophthalmology. Prior to that, Nachman served in various roles with increased scope and responsibilities, including worldwide president of Biosense Webster and Cordis.
 
“I am thrilled to be joining the AtriCure Board during this exciting time of accelerating growth and profitability,” Nachman stated. “I have had a front-row seat in witnessing the incredible growth of the Afib treatment market. That said, there is an abundance of untapped opportunity and AtriCure is at the forefront of treating a segment of the market that includes patients who are significantly underserved. I have done extensive diligence on the company’s business, prospects, and end user markets, and believe them to be significantly underpenetrated. During my time at Biosense Webster, I got to know the unique challenges that clinicians face in treating long-standing persistent Afib, for patients both with and without underlying structural heart disease. The unique combination of products and a foundation of clinical science to support safety and efficacy, has the company poised to continue its leadership position and execute on a long runway of growth.”
  
AtriCure Inc. provides technologies for treating Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons worldwide use AtriCure technologies for treating Afib and reducing Afib-related complications. AtriCure’s Isolator Synergy Ablation System is the first medical device to receive U.S. Food and Drug Administration approval for treating persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AF Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.